Malignant Melanoma in Turkey: A Single Institution's Experience on 475 Cases

Background This study was performed to determine the characteristics and the clinical outcomes of patients with cutaneous melanoma in Turkey. Methods The medical records of patients between 1991 and 2003 at Institute of Oncology were retrieved from the cancer registry. Results Of the 475 adult cases...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Japanese journal of clinical oncology 2006-12, Vol.36 (12), p.794-799
Hauptverfasser: Tas, Faruk, Kurul, Sidika, Camlica, Hakan, Topuz, Erkan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 799
container_issue 12
container_start_page 794
container_title Japanese journal of clinical oncology
container_volume 36
creator Tas, Faruk
Kurul, Sidika
Camlica, Hakan
Topuz, Erkan
description Background This study was performed to determine the characteristics and the clinical outcomes of patients with cutaneous melanoma in Turkey. Methods The medical records of patients between 1991 and 2003 at Institute of Oncology were retrieved from the cancer registry. Results Of the 475 adult cases with complete staging procedure, the incidence of localized (stages I–II) disease was 301 (63.4%), and followed by node involved (stage III) and metastatic (stage IV) disease with the incidence of 117 (24.6%) and 57 (12.0%), respectively. The median age of patients was 50 years (17–104 years) and male/female ratio was 1.1. Of 206 patients (43.4%) the diseases were located on extremities, 150 (31.6%) on the trunk, and 102 (21.5%) on the head and neck region. In cases with early/node negative stage, stage distribution was identical. The superficial spreading type was the commonest histology (52.2%). The Breslow thickness distributed equally, whereas tumor invasion aggregated mainly at Clark level III and IV. Half of the lesions were ulcerated and with low mitotic potential. In cases with the node involved stage, the majority of patients had only one lymph node involved. In metastatic patients, two thirds had distant metastases including lung metastases and half of them had single metastatic region. With the median follow-up of all patients of 5.2 years, the median overall survival of all patients was 62.2 months and the 5-year overall survival was 50.5%. Overall survival was significantly negatively correlated with male (P
doi_str_mv 10.1093/jjco/hyl114
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68284313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jjco/hyl114</oup_id><sourcerecordid>1317874551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-7ebb83f6a399be49be904037f9b6f1d16e7f00f45b28d64c1598723680605f143</originalsourceid><addsrcrecordid>eNqFkEFPGzEQRi3UqqS0J-7I6oEeqi2etdf2ckMRFKSgHpoixMXybmbBYWMHe1ci_x6jREXi0sPMXJ4-vfkIOQT2E1jNT5bLNpw8bHoAsUcmIGRVcFnCBzJhXOqi1AD75HNKS8ZYpYX6RPZBMckEqydkdm17d--tH-g19taHlaXO0_kYH3FzSs_oH-fve6RXPg1uGAcX_PdEz5_XGB36FmnwVKiKTm3C9IV87Gyf8OvuHpC_F-fz6WUx-_3rano2K1ohxFAobBrNO2l5XTco8tRZhquubmQHC5CoOsY6UTWlXkjRQlVrVeZfsnTVgeAH5Hibu47hacQ0mJVLLfbZH8OYjNSlFhx4Br-9A5dhjD67mRIUgM4rQz-2UBtDShE7s45uZePGADOvDZvXhs224Uwf7SLHZoWLN3ZX6ZtcGNf_SSq2oEsDPv9DbXw0UnFVmcvbO1PWt3Nd3Uhzw18AKlCRVA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217118171</pqid></control><display><type>article</type><title>Malignant Melanoma in Turkey: A Single Institution's Experience on 475 Cases</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Tas, Faruk ; Kurul, Sidika ; Camlica, Hakan ; Topuz, Erkan</creator><creatorcontrib>Tas, Faruk ; Kurul, Sidika ; Camlica, Hakan ; Topuz, Erkan</creatorcontrib><description>Background This study was performed to determine the characteristics and the clinical outcomes of patients with cutaneous melanoma in Turkey. Methods The medical records of patients between 1991 and 2003 at Institute of Oncology were retrieved from the cancer registry. Results Of the 475 adult cases with complete staging procedure, the incidence of localized (stages I–II) disease was 301 (63.4%), and followed by node involved (stage III) and metastatic (stage IV) disease with the incidence of 117 (24.6%) and 57 (12.0%), respectively. The median age of patients was 50 years (17–104 years) and male/female ratio was 1.1. Of 206 patients (43.4%) the diseases were located on extremities, 150 (31.6%) on the trunk, and 102 (21.5%) on the head and neck region. In cases with early/node negative stage, stage distribution was identical. The superficial spreading type was the commonest histology (52.2%). The Breslow thickness distributed equally, whereas tumor invasion aggregated mainly at Clark level III and IV. Half of the lesions were ulcerated and with low mitotic potential. In cases with the node involved stage, the majority of patients had only one lymph node involved. In metastatic patients, two thirds had distant metastases including lung metastases and half of them had single metastatic region. With the median follow-up of all patients of 5.2 years, the median overall survival of all patients was 62.2 months and the 5-year overall survival was 50.5%. Overall survival was significantly negatively correlated with male (P&lt;0.001), advanced stages (P&lt;0.001) and old ages (P=0.005). The five-year survival rates of patients with stages I–II and III disease were 63.6% and 36.6%, respectively. Nodular histology subtype, deeper Breslow tumor depth, extensive invasion, presence of ulceration, advanced stage, presence of relapse, being male and elderly patient, presence of visceral recurrence, and high mitotic activity were found to be associated with poor prognosis for overall survival in localized disease. The median survival of metastatic patients was 9.9 months and 1-year overall survival rate was 32.7%. Unresponsiveness to chemotherapy, visceral metastasis, multiple metastases and not given chemotherapy were the poor prognostic factors for overall survival. Conclusion The descriptive and prognostic factors in Turkey are similar to those in Western countries.</description><identifier>ISSN: 0368-2811</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyl114</identifier><identifier>PMID: 17060409</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adolescent ; Adult ; Age Distribution ; Age of Onset ; Aged ; Aged, 80 and over ; Female ; Humans ; Incidence ; Lymphatic Metastasis ; Male ; melanoma ; Melanoma - epidemiology ; Melanoma - pathology ; Melanoma - secondary ; Middle Aged ; Prognosis ; prognostic factor ; Skin Neoplasms - epidemiology ; Skin Neoplasms - pathology ; Skin Neoplasms - secondary ; Survival Rate ; Turkey ; Turkey - epidemiology</subject><ispartof>Japanese journal of clinical oncology, 2006-12, Vol.36 (12), p.794-799</ispartof><rights>2006 Foundation for Promotion of Cancer Research 2006</rights><rights>2006 Foundation for Promotion of Cancer Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-7ebb83f6a399be49be904037f9b6f1d16e7f00f45b28d64c1598723680605f143</citedby><cites>FETCH-LOGICAL-c444t-7ebb83f6a399be49be904037f9b6f1d16e7f00f45b28d64c1598723680605f143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17060409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tas, Faruk</creatorcontrib><creatorcontrib>Kurul, Sidika</creatorcontrib><creatorcontrib>Camlica, Hakan</creatorcontrib><creatorcontrib>Topuz, Erkan</creatorcontrib><title>Malignant Melanoma in Turkey: A Single Institution's Experience on 475 Cases</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>Background This study was performed to determine the characteristics and the clinical outcomes of patients with cutaneous melanoma in Turkey. Methods The medical records of patients between 1991 and 2003 at Institute of Oncology were retrieved from the cancer registry. Results Of the 475 adult cases with complete staging procedure, the incidence of localized (stages I–II) disease was 301 (63.4%), and followed by node involved (stage III) and metastatic (stage IV) disease with the incidence of 117 (24.6%) and 57 (12.0%), respectively. The median age of patients was 50 years (17–104 years) and male/female ratio was 1.1. Of 206 patients (43.4%) the diseases were located on extremities, 150 (31.6%) on the trunk, and 102 (21.5%) on the head and neck region. In cases with early/node negative stage, stage distribution was identical. The superficial spreading type was the commonest histology (52.2%). The Breslow thickness distributed equally, whereas tumor invasion aggregated mainly at Clark level III and IV. Half of the lesions were ulcerated and with low mitotic potential. In cases with the node involved stage, the majority of patients had only one lymph node involved. In metastatic patients, two thirds had distant metastases including lung metastases and half of them had single metastatic region. With the median follow-up of all patients of 5.2 years, the median overall survival of all patients was 62.2 months and the 5-year overall survival was 50.5%. Overall survival was significantly negatively correlated with male (P&lt;0.001), advanced stages (P&lt;0.001) and old ages (P=0.005). The five-year survival rates of patients with stages I–II and III disease were 63.6% and 36.6%, respectively. Nodular histology subtype, deeper Breslow tumor depth, extensive invasion, presence of ulceration, advanced stage, presence of relapse, being male and elderly patient, presence of visceral recurrence, and high mitotic activity were found to be associated with poor prognosis for overall survival in localized disease. The median survival of metastatic patients was 9.9 months and 1-year overall survival rate was 32.7%. Unresponsiveness to chemotherapy, visceral metastasis, multiple metastases and not given chemotherapy were the poor prognostic factors for overall survival. Conclusion The descriptive and prognostic factors in Turkey are similar to those in Western countries.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Distribution</subject><subject>Age of Onset</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>melanoma</subject><subject>Melanoma - epidemiology</subject><subject>Melanoma - pathology</subject><subject>Melanoma - secondary</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>prognostic factor</subject><subject>Skin Neoplasms - epidemiology</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - secondary</subject><subject>Survival Rate</subject><subject>Turkey</subject><subject>Turkey - epidemiology</subject><issn>0368-2811</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEFPGzEQRi3UqqS0J-7I6oEeqi2etdf2ckMRFKSgHpoixMXybmbBYWMHe1ci_x6jREXi0sPMXJ4-vfkIOQT2E1jNT5bLNpw8bHoAsUcmIGRVcFnCBzJhXOqi1AD75HNKS8ZYpYX6RPZBMckEqydkdm17d--tH-g19taHlaXO0_kYH3FzSs_oH-fve6RXPg1uGAcX_PdEz5_XGB36FmnwVKiKTm3C9IV87Gyf8OvuHpC_F-fz6WUx-_3rano2K1ohxFAobBrNO2l5XTco8tRZhquubmQHC5CoOsY6UTWlXkjRQlVrVeZfsnTVgeAH5Hibu47hacQ0mJVLLfbZH8OYjNSlFhx4Br-9A5dhjD67mRIUgM4rQz-2UBtDShE7s45uZePGADOvDZvXhs224Uwf7SLHZoWLN3ZX6ZtcGNf_SSq2oEsDPv9DbXw0UnFVmcvbO1PWt3Nd3Uhzw18AKlCRVA</recordid><startdate>200612</startdate><enddate>200612</enddate><creator>Tas, Faruk</creator><creator>Kurul, Sidika</creator><creator>Camlica, Hakan</creator><creator>Topuz, Erkan</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200612</creationdate><title>Malignant Melanoma in Turkey: A Single Institution's Experience on 475 Cases</title><author>Tas, Faruk ; Kurul, Sidika ; Camlica, Hakan ; Topuz, Erkan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-7ebb83f6a399be49be904037f9b6f1d16e7f00f45b28d64c1598723680605f143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Distribution</topic><topic>Age of Onset</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>melanoma</topic><topic>Melanoma - epidemiology</topic><topic>Melanoma - pathology</topic><topic>Melanoma - secondary</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>prognostic factor</topic><topic>Skin Neoplasms - epidemiology</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - secondary</topic><topic>Survival Rate</topic><topic>Turkey</topic><topic>Turkey - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tas, Faruk</creatorcontrib><creatorcontrib>Kurul, Sidika</creatorcontrib><creatorcontrib>Camlica, Hakan</creatorcontrib><creatorcontrib>Topuz, Erkan</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tas, Faruk</au><au>Kurul, Sidika</au><au>Camlica, Hakan</au><au>Topuz, Erkan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Malignant Melanoma in Turkey: A Single Institution's Experience on 475 Cases</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2006-12</date><risdate>2006</risdate><volume>36</volume><issue>12</issue><spage>794</spage><epage>799</epage><pages>794-799</pages><issn>0368-2811</issn><eissn>1465-3621</eissn><abstract>Background This study was performed to determine the characteristics and the clinical outcomes of patients with cutaneous melanoma in Turkey. Methods The medical records of patients between 1991 and 2003 at Institute of Oncology were retrieved from the cancer registry. Results Of the 475 adult cases with complete staging procedure, the incidence of localized (stages I–II) disease was 301 (63.4%), and followed by node involved (stage III) and metastatic (stage IV) disease with the incidence of 117 (24.6%) and 57 (12.0%), respectively. The median age of patients was 50 years (17–104 years) and male/female ratio was 1.1. Of 206 patients (43.4%) the diseases were located on extremities, 150 (31.6%) on the trunk, and 102 (21.5%) on the head and neck region. In cases with early/node negative stage, stage distribution was identical. The superficial spreading type was the commonest histology (52.2%). The Breslow thickness distributed equally, whereas tumor invasion aggregated mainly at Clark level III and IV. Half of the lesions were ulcerated and with low mitotic potential. In cases with the node involved stage, the majority of patients had only one lymph node involved. In metastatic patients, two thirds had distant metastases including lung metastases and half of them had single metastatic region. With the median follow-up of all patients of 5.2 years, the median overall survival of all patients was 62.2 months and the 5-year overall survival was 50.5%. Overall survival was significantly negatively correlated with male (P&lt;0.001), advanced stages (P&lt;0.001) and old ages (P=0.005). The five-year survival rates of patients with stages I–II and III disease were 63.6% and 36.6%, respectively. Nodular histology subtype, deeper Breslow tumor depth, extensive invasion, presence of ulceration, advanced stage, presence of relapse, being male and elderly patient, presence of visceral recurrence, and high mitotic activity were found to be associated with poor prognosis for overall survival in localized disease. The median survival of metastatic patients was 9.9 months and 1-year overall survival rate was 32.7%. Unresponsiveness to chemotherapy, visceral metastasis, multiple metastases and not given chemotherapy were the poor prognostic factors for overall survival. Conclusion The descriptive and prognostic factors in Turkey are similar to those in Western countries.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>17060409</pmid><doi>10.1093/jjco/hyl114</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0368-2811
ispartof Japanese journal of clinical oncology, 2006-12, Vol.36 (12), p.794-799
issn 0368-2811
1465-3621
language eng
recordid cdi_proquest_miscellaneous_68284313
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adolescent
Adult
Age Distribution
Age of Onset
Aged
Aged, 80 and over
Female
Humans
Incidence
Lymphatic Metastasis
Male
melanoma
Melanoma - epidemiology
Melanoma - pathology
Melanoma - secondary
Middle Aged
Prognosis
prognostic factor
Skin Neoplasms - epidemiology
Skin Neoplasms - pathology
Skin Neoplasms - secondary
Survival Rate
Turkey
Turkey - epidemiology
title Malignant Melanoma in Turkey: A Single Institution's Experience on 475 Cases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T02%3A53%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Malignant%20Melanoma%20in%20Turkey:%20A%20Single%20Institution's%20Experience%20on%20475%20Cases&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Tas,%20Faruk&rft.date=2006-12&rft.volume=36&rft.issue=12&rft.spage=794&rft.epage=799&rft.pages=794-799&rft.issn=0368-2811&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyl114&rft_dat=%3Cproquest_cross%3E1317874551%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217118171&rft_id=info:pmid/17060409&rft_oup_id=10.1093/jjco/hyl114&rfr_iscdi=true